Navigation Links
Neurocrine Biosciences Presents Elagolix Data
Date:6/16/2009

osis suffer from both efficacy and safety shortcomings. The current standards of care such as contraceptives and analgesics (non-steroidal anti-inflammatory drugs) are often ineffective in controlling the symptoms of endometriosis. Likewise, while peptide gonadotropin-releasing hormone (GnRH) agonists such as Lupron(R) (leuprolide acetate) and Zoladex(R) (goserelin acetate) are highly effective in controlling symptoms of endometriosis, these products cause an initial, transient heightening in symptom severity, as well as hot flashes throughout the course of therapy. Most importantly, because all GnRH agonists suppress estrogen to very low levels, long-term treatment is not possible due to the severe bone loss that occurs in patients.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH pr
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
2. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Reports First Quarter 2008 Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
7. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
9. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
10. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... Aug. 29, 2014  A Boston Scientific Corporation ... on stent removability and preliminary long term stricture ... in the August issue of the peer-reviewed journal, ... is being conducted in 11 countries and ... self-expanding metal stents (FCSEMS) after extended indwell (i.e., ...
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... May 20 The owner and operator of a Houston-area ... program, announced the Departments of Justice and Health and Human Services (HHS). ... William M. ... fraud before U.S. District Judge David Hittner in U.S. District ...
... May 20 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of rapid ... Citi Global Health Care Conference being held May 26 through ... New York City .  Jon Russell, Vice President, Finance, will attend. ...
Cached Medicine Technology:Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 2Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 3
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. 30, ... experimental drug was more effective than standard treatment at ... According to the study authors, the trial was stopped ... drug, dubbed LCZ696. In the trial, 26.5 ... either died or were hospitalized due to heart failure, ...
(Date:9/1/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- Watching action shows ... study contends. People eat much more snack food while ... to the Cornell University researchers. "We find that if ... see more action too," study author Aner Tal, of the ... release. "In other words, the more distracting the program is, ...
(Date:9/1/2014)... London, UK (PRWEB) September 01, 2014 ... in developing more effective treatments for Alzheimer's disease ... disease. Uncertainties also exist regarding the diagnosis of ... hence, the lack of appropriate diagnostic tests. ... range of the greatest breakthroughs in the medicine ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( ... litigation that continues to progress in the U.S. District ... , A federal Case List published on August ... cholesterol medication by plaintiffs who developed Type 2 diabetes ... Inc. failed to adequately warn patients and their doctors ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment ... markets (the US, France, Italy, Germany, Spain and the ... by 2018. , The competitive landscape in the B-cell ... and the UK is poised to undergo a dramatic ... four largest B-cell NHL indications, which includes Diffuse Large ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... Nov. 29 Boston Scientific,Corporation (NYSE: BSX ... Food,and Drug Administration (FDA) advisory panel to approve ... stent system. The,PROMUS and XIENCE V stent systems ... Abbott in international markets. Both stent,systems would be ...
... 29 "CT scans are helping to,save countless ... disorders. Indeed, the New England Journal of Medicine ... one of the top 11,innovations of the past ... that detect and treat life threatening diseases CT,scans ...
... International Website goes beyond, Typical ,Best, and ... Affecting ... Determining health risks and the,quality of medical care ... published MEDEX 360m International Healthcare Rating,System, high standards of ...
... November 29 Bavarian Nordic,reports the successful completion ... healthy subjects who received either one or two ... of this,study are seen as the pivotal step ... registration trials in order to achieve a BLA ...
... genetics appear to be key factors, researchers say , , ... -- over and above socio-economic factors -- appear to ... breast cancer, U.S. researchers are reporting. , One new ... cancer patients and their white counterparts, indicating that cancer ...
... by a University of Pennsylvania biologist in the tick-infested woods ... that mice are the main animal reservoir for Lyme disease ... Proceedings of the Royal Society B, demonstrates that chipmunks and ... that account for major outbreaks. , According to the study, white-footed ...
Cached Medicine News:Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 3Health News:Statement by MITA Vice President Andrew Whitman on the Benefits of CT Scans Relative to Radiation Dose Risks 2Health News:MEDEX 360m Rates the State of Global Medical Care for Travelers 2Health News:Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate 2Health News:Studies Reveal Why Breast Cancer Hits Black Women Harder 2Health News:Studies Reveal Why Breast Cancer Hits Black Women Harder 3Health News:University of Pennsylvania study reveals inconspicuous hosts in the Lyme disease epidemic 2
Toxoplasma IgG II ELISA...
ELISA kit for CMV CAP M....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of small sized foreign bodies....
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Medicine Products: